drugset / Trial / NCT00879749
Safety Study of Nexvax2 in Subjects With Coeliac Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main purpose of this study is to determine the safety of weekly injections of Nexvax2 given for three weeks to patients with coeliac disease who have been on a gluten-free diet. The second purpose of this study is to compare the immune response over the three week study period in coeliac disease patients given Nexvax2 compared to those given saline.
Timeline
- Start
- 2009-04
- Primary completion
- 2010-03
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nexvax2 | Peptide | 9 ug | Other |
| Subject | Nexvax2 | Peptide | 30 ug | Other |
| Subject | Nexvax2 | Peptide | 60 ug | Other |
| Subject | Nexvax2 | Peptide | 90 ug | Other |
| Subject | Nexvax2 | Peptide | 900 ug | Other |